Recent News and Articles on the Keywords: alzheimers + offer + modest  Related to the article below (Last Update: 8/7/2008)

Can Alzheimer's drug halt progress? Healthcare Republic - Aug 6, 2008 'This was a modest-sized trial of people with mild and moderate Alzheimer's disease. Larger scale trials are needed to confirm its safety, ... Ontario Now Alzheimer's drug trial 'promise' BBC News, UK - Jul 17, 2008 "These initial findings imply that dimebon could be more effective than treatments currently licensed for people with Alzheimer's, however this was a modest ... Medivation Announces Publication in The Lancet of Dimebon Pivotal ... FOXBusiness all 353 news articles »  MDVN - OTC:CMTX Biotech BOOM Las Vegas Business Press, NV - Aug 4, 2008 At the same time, whatever success boosters score may be modest and will have to come against the more than 40 states that now have some sort of formal ... Home genetic tests: How much do you really want to know? Independent, UK - Jul 11, 2008 For a more modest $2500 you can get the California firm Navigenics to screen nearly two million genetic markers. It all adds up. Myriad Genetics, the mother ... FinFacts Ireland Thursday Newspaper Review - Irish Business News and International ... FinFacts Ireland, Ireland - Jul 30, 2008 But the market took fright at several issues that emerged in a detailed presentation of Phase II clinical trial data to the Alzheimer's Association's ... Walkers and joggers step into cemeteries for serenity by the mile Sacramento Bee,  USA - Jul 24, 2008 In fact, the July 26 inaugural City of Sacramento 5K Championship, a part of the Alzheimer's Aid Society Memorial 5K Run/Walk, will start and end in East ... Biotech Careers: Smart Choices Kiplinger.com, DC - Jul 25, 2008 Caveat: Before obtaining a research professorship, you may need to take a modest-paying two-to-six-year post-doctoral appointment. It's also quite possible ... National Journal Q&A: David Obey National Journal, DC - Aug 1, 2008 We can either capitulate and adopt his budget exactly as he sent it down, or we can insist on exercising the power of the purse to a modest degree. ... Lowering Blood Pressure May Reduce Dementia in the Elderly MedPage Today, NJ - Jul 8, 2008 Investigators in the Syst-Eur trial, achieved the greatest reduction in dementia with a calcium channel blocker in contrast to the more modest results with ... Novartis gains momentum with strong performance in first half of ... Ad-Hoc-News (Pressemitteilung), Germany - Jul 16, 2008 Higher deliveries of poliovaccines and blood testing diagnostics helped offset a modest declinein TBE vaccines, with sales limited by capacity. ...NVS - BOM:500672 - ACL

Alzheimer's drugs offer modest improvements, equal effectiveness

The Alzheimer's drugs Aricept ( Donepezil ), Razadyne ( Galantamine ) and Exelon ( Rivastigmine ) can lead to small improvements in mental functioning and the ability to carry out everyday activities in people with mild to moderate forms of the disease, according to a review of recent studies.
Although the three drugs work in slightly different ways, the few head-to-head studies of the drugs, found them equally effective, according to review author Jacqueline Birks of the University of Oxford.

The review is published in The Cochrane Library, a publication of The Cochrane Collaboration.

Birks' review included 13 high-quality studies involving 7,298 patients from North America, Europe and Australia. The studies compared the three drugs against placebo treatment, with 2,228 patients in the Aricept studies, 2,267 in the Razadyne studies and 2,803 in the Exelon studies.

The effects of the drugs were not very large when measured across the 13 studies, Birks found. In one measure of how well the drugs worked, for instance, patients across the studies improved by an average of less than three points on a 70-point scale that tracks mental functioning.

" There is nothing to suggest the effects are less for patients with severe dementia, although there is very little evidence for other than mild to moderate dementia," she said.

Side effects caused about 29 percent of the patients taking the drugs to leave the studies, compared with 18 percent dropout among the patients taking a placebo. The most common side effects were nausea, vomiting and diarrhea.

Birks found fewer reported side effects among patients taking Aricept, but she suggests that this may have to do with the way Aricept and the other two drugs are prescribed.

Razadyne and Exelon have a "ramp-up" period in which patients take increasingly higher doses to get to a therapeutic level of treatment. Birks says the two drugs may be as tolerable as Aricept if they are gradually introduced over a course of three months.

In a second review focusing on Aricept only, Birks and researcher Richard Harvey found that a 5 milligram a day dose of the drug was only slightly less effective than a 10 milligram a day dose, with fewer side effects.

In another, newly updated Cochrane review, Clement Loy of Garvan Institute of Medical Research in Australia and colleagues concluded that Razadyne can improve or maintain mental functioning at a 16 milligram a day dose.

The three drugs are from a class of medicines called cholinesterase inhibitors. They boost chemical signaling in a group of brain neurons that are typically destroyed during the course of Alzheimer's disease.

Birks said there is no way to know ahead of time whether the inhibitors will work on a particular Alzheimer's patient, but some researchers recommend starting the treatment as soon as possible after a diagnosis.

George Grossberg, at the Saint Louis University School of Medicine, said there is ample evidence that "the earlier one starts the better" for slowing the progression of the disease.

" In fact, patients who come to drugs later, even as little as six months later, never catch up with those who were on drug from the outset," of their diagnosis, Grossberg said.

Although the review of Aricept showed that the drug can be effective even 52 weeks after the start of treatment, Birks says more long term studies of the medicines are needed.

" As Alzheimer's disease generally progresses slowly and clinical course of five to 10 years is not unusual, clinical trials of six or 12 month duration are of limited use," she noted.

Longer trials could also provide more information on whether these drugs are cost-effective treatments. For the moment, there is only limited data on how these drugs affect the overall cost of care for Alzheimer's patients, Birks found.

Source: Center for the Advancement of Health, 2006